Key Highlights: Implications: ChrysCapital’s planned 20–25% stake in Linux Laboratories values the CNS‑focused branded‑generics company at roughly ₹2,400–3,000 crore, reflecting ...
Key Highlights: Implications: The demerger splits India Glycols into three focused companies—chemicals/industrial gases (India Glycols), spirits/biofuels (IGL Spirits), and bio‑pharma/bio‑...
Key Highlights: Implications: By targeting high‑value, time‑sensitive medical logistics (radioactive isotopes, organs, emergency transfers) and airport parts delivery, the SkyDrive–Air Ind...
Key Highlights: Implications: Mankind Pharma’s exclusive agreement with Chongqing Chenan adds two insulin analogues to its India portfolio, strengthening its position in the injectable diabetes segmen...
Key Highlights: Implications: Hearzap’s acquisition of Amplifon India’s hearing care business instantly adds ~240 points of sale (including 115 directly operated centres), clinical teams and an establ...
Key Highlights: Implications: Piramal Pharma’s move to 74% ownership of Yapan Bio for ₹76 crore turns the Hyderabad CDMO into a subsidiary, giving Piramal tighter control over Yapan’s process developm...
Key Highlights: Implications: The Elephas–Neuberg partnership brings a functional, live‑tissue test for immunotherapy response into India’s mainstream diagnostics, giving oncologists an&nb...
Key Highlights: Implications: Biodeal’s ₹385 crore raise gives it the capital to scale up manufacturing, add new products, and enter more regulated markets, which should help it win bigger, longer-ter...
Key Highlights: Implications: For Novartis India, bringing these brands back in‑house supports a more controlled go‑to‑market under new PE ownership and aligns with its plan to insta...
Key Highlights: Implications: By embedding dynamic QR codes and invoice-linked payment links with automatic bill‑by‑bill reconciliation, the solution can materially cut cash handling, spee...
